drugset / Trial / NCT00517218

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

NCT00517218

Phase 3 Withdrawn Genta Incorporated
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and rituximab versus combination treatment with fludarabine and rituximab in previously untreated subjects with CLL.

Timeline

Start
2006-06
Primary completion
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject oblimersen sodium Antisense oligonucleotide

Indications